138 Synthetic re-direction of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors

• Tom Lee,
• Mochtar Pribadi,
• Yijia Pan,
• Hui-Yi Chu,
• Bob Valamehr,
• Dan Lu,
• Philip Chu,
• Amit Mehta,
• Alec Witty,
• Eigen Peralta,
• Emily Carron,
• Lorraine Loter,
• Natalie Navarrete,
• Arvin Tam,
• Kenyon Lyon

Affiliations

Tom Lee

1Fate Therapeutics, San Diego, CA, USA

Mochtar Pribadi

1Fate Therapeutics, San Diego, CA, USA

Yijia Pan

1Fate Therapeutics, San Diego, CA, USA

Hui-Yi Chu

1Fate Therapeutics, San Diego, CA, USA

Bob Valamehr

2Fate Therapeutics, Inc., San Diego, CA, USA

Dan Lu

1Kadmon Corporation, New York, NY, USA

Philip Chu

2Duke University School of Medicine

Amit Mehta

Fate Therapeutics, Inc., San Diego, CA, USA

Alec Witty

Fate Therapeutics, Inc., San Diego, CA, USA

Eigen Peralta

Fate Therapeutics, Inc., San Diego, CA, USA

Emily Carron

Fate Therapeutics, Inc., San Diego, CA, USA

Lorraine Loter

Fate Therapeutics, Inc., San Diego, CA, USA

Natalie Navarrete

Fate Therapeutics, Inc., San Diego, CA, USA

Arvin Tam

Fate Therapeutics, Inc., San Diego, CA, USA

Kenyon Lyon

Fate Therapeutics, Inc., San Diego, CA, USA